Hidrasec (Racecadotril)

Hidrasec is indicated for the symptomatic treatment of acute watery diarrhea, a common condition that can lead to dehydration if not managed promptly.

• Management of acute watery diarrhea in adults.
• Adjunct therapy for children with acute gastroenteritis presenting with watery stools.
• Supportive care to reduce stool output while maintaining fluid balance.
• Use in clinical settings where rapid reduction of intestinal secretions is desired.
• May be considered when oral rehydration therapy alone does not sufficiently control stool frequency.
• Can be part of a broader treatment plan that includes dietary adjustments and monitoring of hydration status.

• Racecadotril acts as a peripheral enkephalinase inhibitor. By blocking the enzyme that degrades endogenous enkephalins, it increases the local concentration of these opioid peptides in the intestinal mucosa. The elevated enkephalins bind to opioid receptors on enteric neurons, reducing the secretion of water and electrolytes into the intestinal lumen without affecting intestinal motility. This antisecretory effect helps to limit stool volume in acute watery diarrhea.

Like many medications, Hidrasec may be associated with adverse reactions, most of which are mild and transient.

Common

• Nausea or mild stomach discomfort.
• Headache.
• Dizziness or light‑headedness.
• Transient abdominal cramps.

Serious

• Allergic reactions such as rash, itching, or swelling.
• Severe skin reactions (e.g., Stevens‑Johnson syndrome).
• Anaphylaxis, characterized by difficulty breathing or throat swelling.

Precautions should be taken when Hidrasec is considered for patients with specific health conditions or concurrent therapies.

• Assess hydration status before initiating therapy, especially in vulnerable populations.
• Use with caution in patients with known hypersensitivity to racecadotril or related compounds.
• Monitor for worsening diarrhea, which may indicate an underlying infection requiring separate treatment.
• Consider renal or hepatic impairment as the drug’s elimination may be altered.
• Avoid use in individuals with severe inflammatory bowel disease without medical supervision.
• Pregnant or breastfeeding women should consult a healthcare professional before use.

Potential drug interactions have been identified for racecadotril, and clinicians should review a patient’s medication list before prescribing Hidrasec.

Avoid

• Concomitant use with potent opioid agonists that may mask gastrointestinal symptoms.
• Combination with drugs that significantly alter intestinal motility, such as prokinetics, may reduce efficacy.

Use with caution

• Anticholinergic agents, as they may increase the risk of constipation.
• Non‑steroidal anti‑inflammatory drugs (NSAIDs), which can affect renal function and fluid balance.
• Diuretics, because changes in fluid status could influence the drug’s antisecretory effect.